Troutman Pepper Advises Hikma Pharmaceuticals PLC in $375M Acquisition of Custopharm Inc.
PHILADELPHIA – Troutman Pepper client Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, has acquired Custopharm Inc. from Water Street Healthcare Partners, following approval from the US Federal Trade Commission. Read a company press release about the acquisition.
The combination with Custopharm enhances Hikma’s R&D capabilities and pipeline and expands Hikma’s differentiated U.S. portfolio to nearly 130 commercialized injectable medicines – a more than fivefold increase over the last decade.
The Troutman Pepper team advising Hikma in the acquisition was led by Chris Miller and included Barbara Sicalides, Tim Atkins, Erin Whaley, Judy O’Grady, Samantha Peruto, Sarah Rust Plyant, Ryan Salem, and Kahn Wiedis, among others.
Health sciences is a core practice at Troutman Pepper. The firm has more than 150 attorneys who represent clients such as innovative biotech, pharmaceutical and medical device developers and manufacturers; physicians, hospitals and other health care providers; health insurers and other payors; and a wide range of members of the health care supply chain.
About Troutman Pepper
Troutman Pepper is a national law firm with more than 1,200 attorneys strategically located in 23 U.S. cities. The firm’s litigation, transactional, and regulatory practices advise a
diverse client base, from start-ups to multinational enterprises. The firm provides sophisticated legal solutions to clients’ most pressing business challenges, with depth across industry sectors, including energy, financial
services, health sciences, insurance, and private equity, among others. Learn more at
troutman.com.